glp-1 ncbi GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity Metabolic responses and benefits of

This argument is plausible it reflects a well-documented problem in drug development where unpatentable compounds struggle to attract industry funding regardless of their scientific merit but it should be noted that this explanation, while widely discussed, has not been formally established in the published literature as the primary reason for the evidence gap

It supports the immune system by enhancing the activity of white blood cells

doi: 10.1074/jbc.M508307200

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial

If these symptoms develop, urgent medical evaluation is necessary